WINDLAS Windlas Biotech Q2 FY26 results (Jul–Sep 2025) and concall
Windlas Biotech reported a strong Q2 & H1 FY26, with revenue growing 19% YoY and EPS up 21% YoY, driven by balanced contributions across all three business verticals. Despite a non-cash ESOP impact and some delays in the injectable facility's ramp-up, the company maintained robust gross margin expansion and improved its liquidity. Management emphasized continued investment in capacity and talent, while navigating a subdued industry volume growth and increasing regulatory scrutiny.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 18.7%, net profit up 12.5% against the same quarter last year.
| Line item | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 175 | 187 | 195 | 203 | 210 +20% | 222 +19% |
| EBITDA | 21 | 23 | 25 | 26 | 27 +29% | 29 +26% |
| Net profit | 13 | 16 | 16 | 16 | 18 +38% | 18 +13% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
